259 related articles for article (PubMed ID: 36682218)
21. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
22. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Khalaf DJ; Sunderland K; Eigl BJ; Kollmannsberger CK; Ivanov N; Finch DL; Oja C; Vergidis J; Zulfiqar M; Gleave ME; Chi KN
Eur Urol; 2019 Jun; 75(6):940-947. PubMed ID: 30591354
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
[TBL] [Abstract][Full Text] [Related]
24. Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments.
Parthipan M; Feng G; Breunis H; Timilshina N; Emmenegger U; Hansen A; Tomlinson G; Matthew A; Clarke H; Santa Mina D; Soto-Perez-de-Celis E; Puts M; Alibhai SMH
J Geriatr Oncol; 2024 Apr; 15(3):101720. PubMed ID: 38350343
[TBL] [Abstract][Full Text] [Related]
25. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Vestris PG; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2022 Feb; 82(2):269-275. PubMed ID: 34822183
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
28. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G; Chiuri VE; Giordano M; Alitto AR; Maisano R; Bordonaro R; Cinieri S; Rossetti S; De Placido S; Airoldi M; Galli L; Gasparro D; Ludovico GM; Guglielmini PF; Carella C; Nova P; Aglietta M; Schips L; Beccaglia P; Sciarra A; Livi L; Santini D;
ESMO Open; 2022 Apr; 7(2):100431. PubMed ID: 35405438
[TBL] [Abstract][Full Text] [Related]
29. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
[TBL] [Abstract][Full Text] [Related]
30. A 10-Item Frailty Index Based on a Comprehensive Geriatric Assessment (FI-CGA-10) in Older Adults with Cancer: Development and Construct Validation.
Nishijima TF; Shimokawa M; Esaki T; Morita M; Toh Y; Muss HB
Oncologist; 2021 Oct; 26(10):e1751-e1760. PubMed ID: 34216413
[TBL] [Abstract][Full Text] [Related]
31. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
32. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
[TBL] [Abstract][Full Text] [Related]
33. Assessing frailty in older Indian patients before cancer treatment: Comparative analysis of three scales and their implications for overall survival.
Rao AR; Noronha V; Ramaswamy A; Kumar A; Pillai A; Gattani S; Sehgal A; Kumar S; Castelino R; Pearce J; Dhekale R; Jagtap P; Tripathi V; Satamkar S; Krishnamurthy J; Mahajan S; Daptardar A; Sonkusare L; Deodhar J; Ansari N; Vagal M; Mahajan P; Timmanpyati S; Nookala M; Chitre A; Kapoor A; Gota V; Banavali S; Badwe RA; Prabhash K
J Geriatr Oncol; 2024 Apr; 15(3):101736. PubMed ID: 38428186
[TBL] [Abstract][Full Text] [Related]
34. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P
Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983
[TBL] [Abstract][Full Text] [Related]
35. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
36. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
Lahcene H; Aprikian AG; Vanhuyse M; Hu J; Bladou F; Cury F; Kassouf W; Perreault S; Dragomir A
J Oncol Pharm Pract; 2020 Mar; 26(2):293-305. PubMed ID: 30997868
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer.
Alibhai SM; Aziz S; Manokumar T; Timilshina N; Breunis H
J Geriatr Oncol; 2017 Jan; 8(1):31-36. PubMed ID: 27756545
[TBL] [Abstract][Full Text] [Related]
38. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
[TBL] [Abstract][Full Text] [Related]
39. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal Assessment of Frailty and Quality of Life in Patients Undergoing Head and Neck Surgery.
Thomas CM; Sklar MC; Su J; Xu W; De Almeida JR; Alibhai SMH; Goldstein DP
Laryngoscope; 2021 Jul; 131(7):E2232-E2242. PubMed ID: 33427307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
